Ignite Creation Date:
2024-05-06 @ 8:05 PM
Last Modification Date:
2024-10-26 @ 3:20 PM
Study NCT ID:
NCT06241807
Status:
RECRUITING
Last Update Posted:
2024-02-14
First Post:
2024-01-28
Brief Title:
Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC
Sponsor:
Shandong Cancer Hospital and Institute
Organization:
Shandong Cancer Hospital and Institute
Organization Data
Organization:
Shandong Cancer Hospital and Institute
Class:
OTHER
Study ID:
SDZL-MX-01
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Shandong Cancer Hospital and Institute
Lead Sponsor Class:
OTHER
Responsible Party:
Xue Meng
Responsible Party Title:
MD PhD
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Shandong Cancer Hospital and Institute
Old Name:
None
Old Organization:
None